Yup, but this time we have approached the trial with full knowledge of how the product works (and doesn't) and the failures built into the first clinical strategy. On this basis alone, I suggest there should be more excitement on the cusp of the results of this trial that the last.
would be nice to see a little more push from management, page-30
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
